Journal article
Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).
Authors
Chasen M; Urban L; Schnadig I; Rapoport BL; Poma A; Arora S; Navari RM; Schwartzberg LS; Gridelli C
Journal
Journal of Clinical Oncology, Vol. 33, No. 15_suppl, pp. 9615–9615
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2015
DOI
10.1200/jco.2015.33.15_suppl.9615
ISSN
0732-183X